---
title: "Hikma Pharmaceuticals (HIK) Receives a Buy from Deutsche Bank"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290723338.md"
description: "Deutsche Bank analyst Kane Slutzkin reiterated a Buy rating on Hikma Pharmaceuticals (HIK) on June 22, setting a price target of p1,950.00. The stock closed at p1,487.00. This contrasts with the general market consensus, which suggests a Moderate Buy with an average price target of p1,742.50."
datetime: "2026-06-24T17:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290723338.md)
  - [en](https://longbridge.com/en/news/290723338.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290723338.md)
generator: "portal-rs"
---

# Hikma Pharmaceuticals (HIK) Receives a Buy from Deutsche Bank

Deutsche Bank analyst Kane Slutzkin reiterated a Buy rating on Hikma Pharmaceuticals on June 22 and set a price target of p1,950.00. The company’s shares closed today at p1,487.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Slutzkin is ranked #6644 out of 12264 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hikma Pharmaceuticals with a p1,742.50 average price target.

### Related Stocks

- [HIK.UK](https://longbridge.com/en/quote/HIK.UK.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [Hikma advances its epinephrine nasal spray with multi-market regulatory filings | HKMPF Stock News](https://longbridge.com/en/news/298632525.md)
- [Hikma epinephrine nasal spray filings gain FDA, Europe, UK review acceptance](https://longbridge.com/en/news/298454098.md)
- [Canaccord Genuity Sticks to Their Buy Rating for Itaconix (ITX)](https://longbridge.com/en/news/298336925.md)
- [REG - Michael Hennigan Checkit PLC - Form 8.3 - Checkit plc](https://longbridge.com/en/news/298625777.md)
- [AstraZeneca: Buy Rating Reaffirmed on Camizestrant Upside and Robust Pipeline, Price Target Maintained at 16,500 GBp](https://longbridge.com/en/news/298228954.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**